References
- Lionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Pharmacotherapy 2005; 25 (9): 1174–80.
- Torres HA, Rivero GA, Lewis RE, Hachem R, Raad II, Kontayiannis DP. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2003; 46: 25–8.
- Lass-Flörl C, Kofler G, Kropshofer G et al. In-vitro test- ing susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergilllosis. J Antimicrob Chemother 1998; 42: 497–502.
- Johnson EM, Oakley KL, Radford SA et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000; 45: 85–93.
- Seo K, Akiyoshi H, Ohnishi Y. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flauus. Microbiol Immun 1999; 43: 1017–25.
- Rex JH, Pfaller MA, Walsh TJ et al. Antifungal Susceptibility Testing: Practical Aspect and Current Challenges. Clin Microbiol Rev. 2001; 14 (4): 643–58.
- National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal suscepti-bility testing of yeasts. Approved standard, 2nd ed. NCCLS document M27-A2. Clinical and Laboratory Standards Institute, Villanova, Pa.
- National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal suscepti-bility testing of filamentous fungi. Approved standard. NCCLS document M38-A. Clinical and Laboratory Standards Institute, Villanova, Pa.
- Espinel-Ingroff A, Pfaller M, Erwin E, Jones RN. Interlaboratory evaluation of E test method for testing antifun-gal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medi-um with 2% glucose. J Clin Microbiol 1996; 34: 848–52.
- Warnock DW, Johnson EM, Rogers TRF. Multicenter evaluation of the E test method for antifungal drug susceptibil-ity testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother 1998; 42: 321–31.
- Pfaller MA, Diekema DJ, Messer SA et al. Activities of fluconazole and voriconazole against 1586 recent clinical iso-lates of Candida species determined by broth microdilution, disc diffusion and E test methods: report from the ARTEMIS global antifungal susceptibility program 2001. J Clin Microbiol 2003; 41: 1440–6.
- Rementeria A, Sanchez-Vargas LO, Villar M et al. Comparison of tablet and disk diffusion methods for flukona-zole and voriconazole in vitro activity testing against clinical yeast isolates. J Chemother 2007; 19: 28–33.
- Espinel-Ingroff A. Utility of mould susceptibility testing. Curr Opin Infect Dis. 2003; 16: 527–32.
- Espinel-Ingroff A. Evaluation of Broth Microdilution Testing Parameters and Agar Diffusion Etest Procedure for Testing Susceptibilities of Aspergillus spp. to Caspofungin Acetate (MK-0991). J Clin Microbiol 2003; 41 (1): 403-9.
- Espinel-Ingroff A, Rezusta A. E-Test Method for Testing Susceptibilities of Aspergillus spp. to the New Triazoles Voriconazole and Posaconazole and to Established Antifungal Agents: Comparison with NCCLS Broth Microdilution Method. J Clin Microbiol 2002; 40 (6): 2101–7.
- Szekely A, Johnson EM, Warnock DW. Comparison of E test and broth microdilution methods for antifungal drug sus-ceptibility testing of molds. J Clin Microbiol 1999; 37: 1480–3.
- Ankan S, Paetznick V, Rex JH. Comparative Evalution of Disk Diffusion with Microdilution Assay in Susceptibility Testing of Caspofungin againts Aspergillus and Fusarium Isolates. Antimicrob Agents Chemother 2002; 46 (9): 3084–7.
- Serrano MC, Ramirez M, Morilla D et al. A compara-tive study of the disk diffusion method with the broth microdi-lution and E test methods for voriconazole susceptibility testing of Aspergillus spp. J Antimicrob Chemother 2004; 53: 739–42.
- Lopez-Oviedo E, Aller Al, Martin C et al. Evaluation of disk diffusion method for determining posaconazole suscepti-bility of filamentous fungi: Comparison with CLSI broth microdilution method. Antimicrob Agents Chemother 2006; 50: 1108–11.
- Patterson TF. New agents for treatment of invasive aspergillosis. Clin Infect Dis 2002; 35: 367–9.
- Dannaoui E, Sorel E, Monier MF, Piens MA, Picot S, Persat F. Acquired itraconazole resistance in Aspergillus fumi-gatus. J Antimicrob Chemother 2001; 47: 333–40.
- Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW. Susceptibility Testing of Aspergillus flauus: Inoculum Dependence with Itraconazole and Lack of Correlation between Susceptibility to Amphotericin B in Vitro and Outcome In Vivo. Antimicrob Agents Chemother 2001; 45 (5): 1456–62.
- Walsh T, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogen-esis and treatment of an emerging fungal pathogen resistant to amphotericin. Br J Infect Dis 2003; 188: 305–19
- National Committee for Clinical Laboratory Standards. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts. Approved guideline. NCCLS document M44-A. Clinical and Laboratory Standards Institute, Villanova, Pa.
- Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro sus-ceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401–14.
- Rex JH, Pfaller MA. Has Antifungal Susceptibility Testing Come of Age? Clin Infect Dis 2002; 35: 982–9.
- Martin-Mazuelos E, Peman J, et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother 2003; 52: 365–370.
- Meletiadis J, Mouton JW, et al. Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2002; 40: 2876–2885.
- Singh J, Rimek D, Kappe R. Intrinsic in vitro suscepti-bility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B. Mycoses 2006; 49: 96–103.
- Espinel-Ingroff A. Comparison of three commercial (Etest, YeastOne and Neo-Sensitabs tablet) and disk diffusion (modified M44-A) assays with reference (CLSI M38-A and M27-A2 microdilution) MICs for testing Zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neofor-mans with posaconazole and amphotericin B. J Clin Microbiol 2006; 44 (10): 3616-3622.